Thermo Fisher sees UBS target lift to 730 dollars
UBS upgrades Thermo Fisher to Buy, raising its price target by 190 dollars to 730, citing sustained organic growth prospects in bioprocessing.
Thermo Fisher Scientific received a significant upgrade from UBS, which moved the stock from Neutral to Buy and lifted its price target from 540 dollars to 730 dollars. This new valuation sits approximately 20 percent above the recent trading level of 606 dollars, reflecting strong confidence in the company's ability to maintain mid-single-digit organic revenue growth.
The analyst action positions Thermo Fisher well above the broader market consensus, where the average 12-month target across 29 analysts stands at roughly 638 dollars. UBS’s forecast is driven by improving funding conditions in biotech and bioprocessing, which are expected to support the company’s long-term revenue trajectory.
Earnings Beat Supports Valuation Case
This bullish stance builds on Thermo Fisher’s recent performance for the quarter ended June 2026. The company reported earnings per share of 6.03 dollars, exceeding the consensus estimate of 5.71 dollars, while revenue reached 11.99 billion dollars against expectations of 11.71 billion dollars. This double-digit year-over-year revenue growth of 10.5 percent was accompanied by a net margin of 15.04 percent and a return on equity of 17.09 percent.
Management’s full-year 2026 guidance remains consistent with these strong results, projecting earnings per share between 24.93 and 25.33 dollars. This range aligns closely with the average analyst expectation of 25.13 dollars, providing a stable foundation for the higher valuation targets proposed by optimists like UBS.
Dividend Policy Remains Conservative
Thermo Fisher continues to prioritize capital reinvestment over high shareholder payouts. The company announced a quarterly cash dividend of 0.47 dollars per share, with an ex-dividend date set for September 15, 2026. This translates to an annualized dividend of 1.88 dollars, representing a modest yield of approximately 0.3 percent and a payout ratio of 10.11 percent.
This low payout ratio allows the company to retain substantial cash flow for research, acquisitions, and capacity expansion. By maintaining a conservative dividend policy, Thermo Fisher ensures it has ample resources to fund future growth initiatives while still providing a steady, if small, cash return to investors.
Analyst Views Remain Divided
Despite the UBS upgrade, sentiment among analysts is not uniformly positive. Bernstein maintains a Hold rating on Thermo Fisher with a price target of 575 dollars, which is below the consensus estimate of 641 dollars. This divergence highlights differing views on the stock’s current valuation and its potential upside.
As of September 10, 2026, Thermo Fisher shares were trading at 602.71 dollars on the New York Stock Exchange, a slight decline from the previous session. The stock remains in the upper part of its recent trading range, with market participants weighing the strong earnings backdrop against the mixed analyst recommendations.
